Radiology · free tool
Guideline Finder
The guidelines and RANZCR statements your exam answers should name: what each recommends, a sentence you can write to cite it, what changed recently and the outdated answer to avoid. Quiz yourself, flip flashcards, print a cheat sheet. Free, no sign-up.
40 guidelines · 21 from RANZCR · 8 recently changed · checked 2026-11
You know 0%
RANZCR exam guideline cheat sheet · checked 2026-11 · fellowshipready.com.au
Standards of practice: referral, contrast and communicating urgent findings: Standards of Practice for Clinical Radiology (RANZCR, Version 12.0 (approved November 2025)). Every examination needs a valid referral and a decision on clinical appropriateness before it is accepted; inappropriate requests are discussed with the referrer. Urgent or unexpected findings must be communicated directly to the referrer (or delegate), with a process for when they cannot be reached. Where contrast is given, a trained registered practitioner must be on site, a reaction treatment guide displayed in the room, and the agent and batch recorded. Patients are asked about possible pregnancy or breastfeeding, and identity is confirmed before and after the examination; AI output never replaces the radiologist's report.
Iodinated contrast and kidney function: RANZCR Iodinated Contrast Media Guideline (RANZCR, Version 2.3 (March 2018; under review 2026)). Risk of contrast-associated AKI is likely negligible with eGFR above 45; no special precautions are needed. eGFR 30–45: routine prophylactic hydration is not recommended, except perhaps with acutely worsening function. eGFR below 30 or active AKI: weigh risk against benefit and consider IV 0.9% saline; severe impairment is not an absolute contraindication. Oral hydration is not a substitute for IV fluids, N-acetylcysteine and bicarbonate are not recommended, and age alone should not trigger renal testing.
Metformin and iodinated contrast: RANZCR Iodinated Contrast Media Guideline (RANZCR, Version 2.3 (March 2018; under review 2026)). IV contrast: metformin can continue if eGFR is above 30. If eGFR is below 30 or unknown, or the patient is unwell with deteriorating renal function, withhold metformin for at least 48 hours and check eGFR before restarting. For intra-arterial procedures the threshold is an eGFR of 45. The concern is lactic acidosis if contrast precipitates AKI while metformin accumulates.
Previous contrast reaction: premedication: RANZCR Iodinated Contrast Media Guideline (RANZCR, Version 2.3 (March 2018; under review 2026)). A previous reaction substantially raises the risk of recurrence; consider non-contrast or alternative imaging first. Corticosteroid premedication can reduce the frequency and severity of reactions but has not been shown to reduce deaths. Oral prednisolone must start at least 6 hours before contrast to have any effect (adult regimen 50 mg doses timed before the study). Keep high-risk patients for 30 minutes after injection with the cannula in place.
Acute contrast reaction: first-line treatment: RANZCR Iodinated Contrast Media Guideline (RANZCR, Version 2.3 (March 2018; under review 2026)). For anaphylactoid reactions give IM adrenaline 1:1000 into the anterolateral thigh promptly; do not withhold it over side-effect concerns. Repeat adrenaline every 5 minutes as needed in severe reactions. Consider IV glucagon 1–2 mg if resistant to adrenaline, especially in patients on beta-blockers. Observe for at least 4–6 hours after resolution because biphasic reactions occur.
Iodinated contrast in pregnancy and breastfeeding: RANZCR Iodinated Contrast Media Guideline (RANZCR, Version 2.3 (March 2018; under review 2026)). Iodinated contrast is TGA category B1/B2 and has not been shown to increase malformations; use when clinically indicated. Infants exposed in utero need neonatal thyroid testing, which is covered by routine newborn heel-prick screening in Australia and NZ. Breastfeeding need not be interrupted, and milk does not need to be expressed and discarded. Ask about pregnancy and breastfeeding before contrast as part of safety screening.
Iodinated contrast and the thyroid: RANZCR Iodinated Contrast Media Guideline (RANZCR, Version 2.3 (March 2018; under review 2026)). Untreated hyperthyroidism or an autonomous (hyperfunctioning) nodule increases the risk of iodine-induced thyrotoxicosis. Known or suspected hyperthyroidism should be tested and treated before contrast where possible. Contrast-induced thyrotoxicosis typically appears 3–6 weeks after exposure. Iodinated contrast can block radioiodine/thyroid uptake studies for up to about 8 weeks.
MRI safety: zones, screening and device labelling: RANZCR MRI Safety Guidelines (RANZCR, Version 3.0 (September 2021)). Four zones: public access only to Zones I–II; Zone III is controlled; Zone IV is the scanner room. The 0.5 mT (5 gauss) line is the boundary for pacemaker safety. Three safety screens are recommended, at least two on site, with MRI-trained staff (one senior) doing the later screens. Items are MR Safe, MR Conditional or MR Unsafe; anything without documented status is treated as unsafe.
MRI with pacemakers and ICDs: RANZCR MRI Safety Guidelines (RANZCR, Version 3.0 (September 2021)). MR Conditional cardiac devices are scanned only within their stated conditions, usually with device reprogramming and monitoring. Non-conditional (legacy) devices need a documented risk–benefit decision and written consent. Coordinate with cardiology/device technicians before and after the scan. Keep patients with active devices outside the 0.5 mT line unless being scanned under protocol.
MRI and gadolinium in pregnancy and breastfeeding: RANZCR MRI Safety Guidelines (RANZCR, Version 3.0 (September 2021)). MRI in pregnancy is appropriate when the information is needed before delivery, cannot be obtained with non-ionising alternatives such as ultrasound, and benefit outweighs risk. Gadolinium in pregnancy only when clinically warranted, at the lowest effective dose, with specific consent. Breastfeeding: very little gadolinium reaches milk; a 12–24 hour pause is optional and the mother's choice. Document the indication and discussion.
MRI: SAR limits and acoustic noise: RANZCR MRI Safety Guidelines (RANZCR, Version 3.0 (September 2021)). Whole-body SAR limits: 2 W/kg in normal mode and 4 W/kg in first-level controlled mode. Core temperature rise is kept under 0.5 °C in normal mode; neonates, pregnant, febrile, elderly and cardiovascular patients need closer monitoring. Hearing protection for all patients and anyone in the room during scanning unless documented sound levels are below 85 dB(A). Prevent burns: no skin-to-skin or cable loops, pad contact points, remove unnecessary cables and metallic patches.
MRI emergencies and quench: RANZCR MRI Safety Guidelines (RANZCR, Version 3.0 (September 2021)). For cardiac or respiratory arrest, move the patient out of Zone IV and beyond the 0.5 mT line to a designated resuscitation area. Keep access restrictions in place: arrest teams and equipment must not enter Zone IV. A deliberate quench is reserved for situations where the static field itself is an immediate threat to life (e.g. a person pinned by a ferromagnetic object). The magnet stays on during a routine arrest; turning off the scanner does not remove the static field.
Writing the radiology report: structure: Clinical Radiology Written Report Guidelines (RANZCR, Version 7.0 (November 2020)). Include clinical information, technique (including contrast and any reaction), comparison studies with dates, findings and a conclusion. Answer the referrer's specific question; if it cannot be answered, say why and suggest a better approach. Give the most likely diagnosis or a short ranked differential rather than a long list. State image quality limitations and their effect on interpretation.
Report language, recommendations and addenda: Clinical Radiology Written Report Guidelines (RANZCR, Version 7.0 (November 2020)). Avoid vague hedging phrases such as 'might be consistent with' or 'possibly represents'; use recognised classification systems to express likelihood. Recommendations should be specific and explain how they help; name the type of service, not particular practices or practitioners. Preliminary reports must be marked as unauthorised and subject to change. If a later review changes the diagnosis, inform the clinicians and add a dated addendum; never alter the signed original.
Informed consent for imaging procedures: Medical Imaging Informed Consent Guidelines (RANZCR, Version 3.0 (June 2019)). Written consent is recommended for complex or higher-risk examinations, procedures that breach the skin (other than IV cannulation), and examinations not mainly for clinical care. Disclose material risks: common ones and rarer ones that matter to this patient, plus the consequences of not proceeding; discuss radiation for high-dose studies. The radiologist holds overall responsibility; tasks may be delegated under protocol. Consent can be withdrawn at any time; in emergencies, only what is immediately necessary may proceed without consent.
Procedural sedation by radiologists: Sedation Guidelines for Radiologists (RANZCR, Version 1.0 (approved November 2025)). Radiologist-led sedation is minimal or moderate only; deep sedation needs an anaesthetist. Moderate IV sedation needs at least 3 trained staff, 2 ALS-trained, with one dedicated solely to monitoring. Continuous SpO2 and heart rate, intermittent NIBP, oxygen, suction and defibrillator; capnography optional for prolonged moderate sedation. Discuss with anaesthesia for red flags (ASA ≥4, OSA, age <16 or >75, frailty, BMI <20 or >35, pregnancy); consider GLP-1 agonists when fasting; no driving home.
Interventional radiology standards: consent, checklists and skin dose: Standards of Practice for Interventional Radiology and Interventional Neuroradiology (RANZCR, Version 1.0 (June 2022)). Informed consent by the operator or informed delegate, in advance for elective cases, and reviewed if circumstances change. Safety checklists confirm the correct patient, procedure and site before invasive procedures. Patients with a substantial skin dose need medical physicist dose assessment and follow-up; doses are kept ALARA and high-dose procedures reviewed against national reference levels. Each patient needs a personalised follow-up plan, with clear responsibility for post-procedure care and access to emergency surgical support.
Acute ankle injury: when to image: Choosing Wisely Australia recommendations: The Royal Australian and New Zealand College of Radiologists (RANZCR (Choosing Wisely Australia), Last reviewed April 2016). Diagnose acute ankle injuries with history, examination and selective plain radiographs (clinical decision rules such as the Ottawa rules). Do not use MRI as a first test. Consider MRI only for persistent symptoms suggesting instability or internal derangement after normal weight-bearing radiographs. Avoid imaging that will not change management.
Low back pain: when to image: Choosing Wisely Australia recommendations: The Royal Australian and New Zealand College of Radiologists (RANZCR (Choosing Wisely Australia), Last reviewed April 2016). Imaging is not needed for non-specific low back pain without red flags. Image when there are risk factors or red flags for serious pathology (malignancy, infection, fracture), sciatica that may need intervention, or cauda equina syndrome. Suspected cauda equina is an emergency for urgent MRI. Imaging findings such as degeneration are common in people without pain and can cause harm through over-investigation.
Suspected PE and DVT: avoiding unnecessary imaging: Choosing Wisely Australia recommendations: The Royal Australian and New Zealand College of Radiologists (RANZCR (Choosing Wisely Australia), Last reviewed April 2016). Use clinical decision rules and D-dimer to avoid CTPA in low-risk patients with suspected PE. In ambulatory patients with suspected DVT, a Wells score below 2 plus a negative D-dimer may make ultrasound unnecessary. Imaging is for patients who are not low risk or who have a positive D-dimer. Unnecessary CTPA adds radiation, contrast risk and incidental findings.
Minor head injury and cervical spine trauma: decision rules: Choosing Wisely Australia recommendations: The Royal Australian and New Zealand College of Radiologists (RANZCR with ACEM (Choosing Wisely Australia), Last reviewed April 2016). Use the Canadian CT Head Rule in adults (PECARN in children) to avoid CT in low-risk minor head injury. Use the Canadian C-Spine Rule or NEXUS criteria to avoid cervical spine imaging in low-risk trauma patients. Both are joint recommendations with ACEM. Image those who fail the rule or have high-risk features.
Thyroid nodule: FNA thresholds (TI-RADS): ACR Thyroid Imaging Reporting and Data System (TI-RADS) (American College of Radiology, ACR TI-RADS (2017 white paper; current chart)). Points are summed across composition, echogenicity, shape, margin and echogenic foci to give TR1–TR5. TR3 (3 points): FNA if ≥2.5 cm, follow-up if ≥1.5 cm. TR4 (4–6 points): FNA if ≥1.5 cm, follow-up if ≥1.0 cm. TR5 (≥7 points): FNA if ≥1.0 cm, follow-up if ≥0.5 cm; taller-than-wide, punctate echogenic foci and extrathyroidal extension each score 3.
Liver observations in at-risk patients (LI-RADS CT/MRI): ACR Liver Imaging Reporting and Data System (LI-RADS) CT/MRI (American College of Radiology, CT/MRI v2018 (current core)). Applies only to patients at high risk of HCC: cirrhosis, chronic hepatitis B, or current/prior HCC; not to under-18s or vascular/congenital-fibrosis cirrhosis. Major features: nonrim arterial phase hyperenhancement, nonperipheral washout, enhancing capsule and threshold growth (≥50% in ≤6 months). LR-5 (definite HCC): 10–19 mm with nonrim APHE plus washout or threshold growth; ≥20 mm with nonrim APHE plus one or more additional major features. LR-M: probably or definitely malignant but not HCC-specific (e.g. targetoid); LR-TIV: tumour in vein.
Lung cancer screening CT reporting (Lung-RADS): ACR Lung CT Screening Reporting and Data System (Lung-RADS) (American College of Radiology, v2022). For screening LDCT only; incidental nodules outside screening are managed with Fleischner. v2022 added criteria for atypical cysts and airway nodules, and categories for likely inflammatory or infectious findings (category 0 with 1–3 month LDCT, or 2). Stepped management: stable category 3 at 6 months becomes 2; stable 4A at 3 months becomes 3, then 2. Growth is an increase of more than 1.5 mm in mean diameter within 12 months; slow-growing solid nodules may be 4B.
Adnexal mass risk stratification (O-RADS US): ACR Ovarian-Adnexal Reporting and Data System Ultrasound (O-RADS US) (American College of Radiology, v2022). O-RADS 1: normal ovary or physiological cyst (follicle, corpus luteum). O-RADS 2: typical benign lesions (haemorrhagic cyst, dermoid, endometrioma, paraovarian or peritoneal inclusion cyst, hydrosalpinx). O-RADS 4–5: lesions with solid components; irregular solid lesions or ≥4 papillary projections with colour score 3–4 are O-RADS 5. Ascites or peritoneal nodules not otherwise explained upgrade a lesion to O-RADS 5.
Adnexal masses: IOTA Simple Rules: IOTA Simple Rules (International Ovarian Tumor Analysis (IOTA) group, 2008 (Timmerman et al.)). Five benign (B) and five malignant (M) ultrasound features. Only B features present: benign; only M features: malignant. No features, or both B and M features: inconclusive, needing expert ultrasound or another method. Typical M features include an irregular solid tumour, ascites, ≥4 papillary structures and very strong blood flow; B features include a unilocular cyst and acoustic shadows.
Breast imaging reporting categories (BI-RADS): ACR BI-RADS Atlas (BI-RADS v2025 Manual) (American College of Radiology, v2025 manual (extension of the 5th edition)). Category 0 (incomplete) now distinguishes 'needs additional imaging' from 'needs prior imaging for comparison'. Category 6 (known biopsy-proven malignancy) now points to surgical/oncology follow-up and definitive local therapy, not only excision. Breast density is reported A–D; D (extremely dense) lowers mammographic sensitivity. Calcification terms simplified ('popcorn-like' and 'dystrophic' merged into 'coarse'; 'milk of calcium' renamed 'layering'); 'developing asymmetry' removed; contrast-enhanced mammography integrated.
Incidental pulmonary nodules on CT: Guidelines for Management of Incidental Pulmonary Nodules Detected on CT Images: From the Fleischner Society 2017 (Fleischner Society, 2017). For incidental nodules in adults (35 and over); not for lung cancer screening, immunocompromised patients or known cancer. Single solid nodule <6 mm in a low-risk patient: no routine follow-up. Solid 6–8 mm: CT at 6–12 months; >8 mm: consider CT at 3 months, PET/CT or tissue sampling. Pure ground-glass nodules <6 mm need no routine follow-up; larger or part-solid nodules have longer surveillance because they grow slowly.
National Lung Cancer Screening Program: who is screened: National Lung Cancer Screening Program (Australian Government Department of Health, Disability and Ageing, Program commenced 1 July 2025). Eligible: age 50–70, asymptomatic, current smoker or quit within the past 10 years, and at least 30 pack-years. Screening test is low-dose CT. Participation is recorded through the National Cancer Screening Register. Symptomatic patients need diagnostic CT, not screening LDCT.
Contrast-associated AKI: ACR prophylaxis threshold: ACR Manual on Contrast Media (American College of Radiology (with National Kidney Foundation consensus), Current online edition (chapters updated 2021–2025)). IV fluid prophylaxis is indicated with AKI or severe CKD (eGFR <30) for IV iodinated contrast; not for stable eGFR ≥30 or for patients on dialysis. Prophylaxis may be considered case by case at eGFR 30–44 in very high-risk patients. Metformin need not be stopped if there is no AKI and eGFR is ≥30; withhold for 48 hours with AKI, eGFR <30 or arterial studies risking renal emboli. No need to stop metformin for gadolinium at usual doses.
Gadolinium agents and NSF risk: ACR Manual on Contrast Media: Nephrogenic Systemic Fibrosis chapter (American College of Radiology, NSF chapter updated 2025). Group I agents (gadodiamide, gadopentetate, gadoversetamide) caused most NSF cases. Group II agents (gadobenate, gadobutrol, gadoterate, gadoteridol, gadoxetate; gadopiclenol provisionally) carry very low or possibly no NSF risk at standard doses. Renal function screening before Group II agents is optional; Group II agents are strongly preferred if NSF risk exists. Avoid routine gadolinium in pregnancy; give only when clinical benefit clearly outweighs unknown fetal risk.
Stroke imaging: perfusion selection for reperfusion: Australian and New Zealand Living Clinical Guidelines for Stroke Management (Stroke Foundation, Living guideline (Chapter 3 updated 2024)). Thrombectomy for ICA or proximal M1 occlusion, including 6–24 hours after last known well when CT perfusion or MRI shows salvageable tissue. Alteplase can be given 4.5–9 hours after onset (or wake-up stroke) when perfusion mismatch criteria are met. Tenecteplase or alteplase within 4.5 hours for eligible large vessel occlusion. Imaging must answer: haemorrhage, occlusion site, and salvageable penumbra.
Suspected physical abuse in children: imaging protocol: The radiological investigation of suspected physical abuse in children (Royal College of Radiologists and Society and College of Radiographers (UK), Revised first edition (November 2018)). Skeletal survey always for children under 2; older children case by case. CT head with the survey for under 1s; over 1 if head injury signs or neurological features. Follow-up skeletal survey for all at 11–14 days (no later than 28 days), even if the first was normal. Initial survey acquired and reported within 24 hours (no later than 72), with a consensus report by two radiologists experienced in paediatric imaging.
Paediatric minor head injury: CT or observe: Australian and New Zealand Guideline for Mild to Moderate Head Injuries in Children (PREDICT (Paediatric Research in Emergency Departments International Collaborative), Version 1 (2021; summary 2023)). Immediate CT for GCS ≤13 within 72 hours of injury. GCS 15 within 24 hours and no risk factors: no CT. GCS 14–15 with risk factors: choose between structured observation and CT; consider CT on anticoagulants or antiplatelets. Skull X-ray and skull ultrasound should not replace CT; MRI is not routine primary imaging.
DXA reporting and treatment thresholds: 2024 Royal Australian College of General Practitioners and Healthy Bones Australia guideline for osteoporosis management and fracture prevention in postmenopausal women and men over 50 years of age (RACGP and Healthy Bones Australia, 2024 (MJA summary 2025)). Measure BMD by DXA at the lumbar spine and hip unless a site is unsuitable. A minimal-trauma fracture after 50 implies osteoporosis; be cautious diagnosing from a single mild vertebral deformity, especially under 60. Treat if T-score ≤ −2.5, or −1.5 to −2.5 with FRAX major osteoporotic risk ≥20% and/or hip ≥3%. T-score below −3.0 or a recent fracture marks very high risk.
Diagnostic reference levels and dose optimisation: National Diagnostic Reference Level Service (under Code for Radiation Protection in Medical Exposure, RPS C-5) (ARPANSA, RPS C-5 (2019); NDRLS current). RPS C-5 (section 3.2.15) requires providers to compare typical patient doses regularly with national DRLs. DRLs are benchmarks to trigger protocol optimisation, not dose limits for individual patients. The NDRLS lets facilities compare their doses across modalities and protocols (e.g. CTDIvol and DLP for CT). The aim is ALARA while keeping diagnostic image quality.
Chest imaging: low-value tests (Evolve TSANZ): Evolve Top-5 recommendations: Thoracic Society of Australia and New Zealand (Adult) (RACP Evolve / TSANZ, Current Evolve list (accessed 2026-11)). Avoid D-dimer when PE probability is high; go straight to CTPA. Avoid routine follow-up of solid pulmonary nodules under 6 mm in low-risk patients. Avoid serum ACE to diagnose or monitor sarcoidosis. Avoid long-term systemic steroids and unnecessary maintenance inhalers in COPD.
Neuroimaging: low-value requests (Evolve ANZAN): Evolve Top-5 recommendations: Australian and New Zealand Association of Neurologists (RACP Evolve / ANZAN, Current Evolve list (accessed 2026-11)). No brain imaging for non-acute primary headache (migraine, tension-type) with a normal neurological examination. No carotid imaging for simple syncope without focal neurological symptoms. Do not routinely recommend surgery for asymptomatic carotid stenosis over 50%. Avoid epidural steroid injections for back pain without radicular symptoms.
Thyroid ultrasound for abnormal TFTs (Evolve ESA): Evolve Top-5 recommendations: Endocrine Society of Australia (RACP Evolve / ESA, Current Evolve list (accessed 2026-11)). Do not routinely order thyroid ultrasound for abnormal thyroid function tests when the gland feels normal. Ultrasound is for palpable nodules, goitre or specific structural questions. Unnecessary ultrasound finds incidental nodules that lead to further tests. Other ESA items include not measuring T3 to adjust thyroxine.
Prostate MRI scoring (PI-RADS): Prostate Imaging Reporting and Data System (PI-RADS) (ACR, ESUR and AdMeTech Foundation, v2.1 (2019)). Peripheral zone scoring is driven by DWI/ADC; transition zone scoring by T2-weighted imaging. v2.1: a TZ lesion scoring 2 on T2 is upgraded to overall 3 if DWI scores 4 or 5. v2.1 revised TZ T2 scoring (encapsulated nodules score 1–2) and DWI score 2/3 definitions; DCE negative criteria refined. Acquisition: high b-value of at least 1400 s/mm² is mandatory; DCE temporal resolution 15 seconds or better.
Summaries are written in our own words from each guideline's official page and are for exam study, not clinical use. Guidelines change: check the source before you rely on it.
Try 20 free questions.
RANZCR-style questions, marked with a reason for every option. Free account, no card.
Also free: Anatomy Scroller · RANZCR exam guides